ACT Brief: Intuitive Technology Design and Site Compliance, Vaccine Follow-Up Strategy Optimization, and AI-Driven Antibody Discovery

In today's ACT Brief, we explore how user-friendly technology reduces errors and site workarounds, strategic approaches to combining traditional and real-world data collection for vaccine long-term follow-up, and Merck's collaboration with Infinimmune to accelerate antibody discovery using AI.